Newsfeeds - Spark Newswire

1 minute read

Enanta Pharmaceuticals To Present New Data For EDP-235 In Development As An Oral, Once-daily Treatment For Covid-19, At The International Conference On Antiviral Research

Today, 3:50 PM

Phase 1 Data Demonstrate Favorable Safety, Tolerability and Pharmacokinetics Supportive of Once-Daily Dosing Without Ritonavir Preclinical Animal Data Indicate the Potential for EDP-235 to Reduce Household

ENTA

2 minute read

Enanta Pharmaceuticals To Present New Data For EDP-235, Its 3CL Protease Inhibitor, In Development As An Oral, Once-Daily Treatment For COVID-19, At The 36th International Conference On Antiviral Research

By Happy Mohamed

Today, 3:50 PM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease

ENTA

1 minute read

SVB Leerink Reiterates Market Perform on Enanta Pharma, Maintains $49 Price Target

By Benzinga Newsdesk

Today, 3:50 PM

SVB Leerink analyst Roanna Ruiz reiterates Enanta Pharma (NASDAQ:ENTA) with a Market Perform and maintains $49 price target.

ENTA

1 minute read

JP Morgan Maintains Neutral on Enanta Pharma, Lowers Price Target to $60

By Benzinga Newsdesk

Today, 3:50 PM

JP Morgan analyst Eric Joseph maintains Enanta Pharma (NASDAQ:ENTA) with a Neutral and lowers the price target from $74 to $60.

ENTA

9 minute read

Earnings

Earnings Scheduled For February 7, 2023

By Benzinga Insights

Today, 3:50 PM

Companies Reporting Before The Bell • BP (NYSE:BP) is likely to report quarterly earnings at $1.67 per share on revenue of $53.79 billion.

AAT

1 minute read

HC Wainwright & Co. Initiates Coverage On Enanta Pharmaceuticals with Buy Rating, Announces Price Target of $56

By Benzinga Newsdesk

Today, 3:50 PM

HC Wainwright & Co. analyst Ed Arce initiates coverage on Enanta Pharmaceuticals (NASDAQ:ENTA) with a Buy rating and announces Price Target of $56.

ENTA

1 minute read

RBC Capital Maintains Sector Perform on Enanta Pharmaceuticals, Lowers Price Target to $54

By Benzinga Newsdesk

Today, 3:50 PM

RBC Capital analyst Brian Abrahams maintains Enanta Pharmaceuticals (NASDAQ:ENTA) with a Sector Perform and lowers the price target from $65 to $54.

ENTA

1 minute read

Enanta Pharmaceuticals Q4 EPS $(1.27) Beats $(1.35) Estimate, Sales $20.32M Miss $22.86M Estimate

By Benzinga Newsdesk

Today, 3:50 PM

Enanta Pharmaceuticals (NASDAQ:ENTA) reported quarterly losses of $(1.27) per share which beat the analyst consensus estimate of $(1.35) by 5.93 percent. This is a 4.1 percent decrease over losses of $(1.22) per share

ENTA

3 minute read

Earnings

Earnings Scheduled For November 21, 2022

By Benzinga Insights

Today, 3:50 PM

Companies Reporting Before The Bell • Zepp Health (NYSE:ZEPP) is expected to report quarterly earnings at $0.54 per share on revenue of $186.58 million.

2 minute read

Enanta Pharmaceuticals Presents New Preclinical Data For EDP-235, Its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed For The Treatment Of COVID-19 At IDWeek 2022 On October 21

By Benzinga Newsdesk

Today, 3:50 PM

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced new preclinical data supporting

ENTA